Glycemic optimization over 12 months did not significantly change myocardial triglyceride content (MTGC) in adults with newly diagnosed type 2 diabetes (MTGC 0.52% to 1.05%, p=0.23).
Does a 12-month glycemic optimization protocol improve myocardial steatosis and cardiac remodeling in patients with newly diagnosed type 2 diabetes?
In newly diagnosed type 2 diabetes, early glycemic optimization improves cardiac remodeling parameters, which correlates with reductions in adiposity rather than HbA1c, despite no significant changes in myocardial steatosis.
Absolute Event Rate: 1.05% vs 0.52%
p-value: p=0.23
In patients with newly diagnosed T2D, 12 months of glycemic optimization was associated with changes in cardiac remodeling parameters despite no detectable changes in myocardial steatosis. The observed cardiac changes were more closely associated with concurrent reductions in adiposity markers than with changes in HbA1c, emphasizing weight management as a key target for early prevention of diabetic cardiomyopathy.
Rosales-Rojas et al. (Fri,) conducted a other in Adults with newly diagnosed type 2 diabetes (n=20). Glycemic optimization protocol including insulin glargine, metformin, empagliflozin with nutritional and lifestyle counseling vs. No comparator (single-arm longitudinal study) was evaluated on Change in myocardial triglyceride content (MTGC) assessed by ¹H-MRS (p=0.23). Glycemic optimization over 12 months did not significantly change myocardial triglyceride content (MTGC) in adults with newly diagnosed type 2 diabetes (MTGC 0.52% to 1.05%, p=0.23).